Phenotype diversity in type 1 Gaucher disease: discovering the genetic basis of Gaucher disease/hematologic malignancy phenotype by individual genome analysis. 2012

Sarah M Lo, and Murim Choi, and Jun Liu, and Dhanpat Jain, and Rolf G Boot, and Wouter W Kallemeijn, and Johannes M F G Aerts, and Farzana Pashankar, and Gary M Kupfer, and Shrikant Mane, and Richard P Lifton, and Pramod K Mistry
Section of Pediatric Hematology-Oncology, Department of Pediatrics, Yale School of Medicine, 333 Cedar St., New Haven, CT 06520, USA.

Gaucher disease (GD), an inherited macrophage glycosphingolipidosis, manifests with an extraordinary variety of phenotypes that show imperfect correlation with mutations in the GBA gene. In addition to the classic manifestations, patients suffer from increased susceptibility to hematologic and nonhematologic malignancies. The mechanism(s) underlying malignancy in GD is not known, but is postulated to be secondary to macrophage dysfunction and immune dysregulation arising from lysosomal accumulation of glucocerebroside. However, there is weak correlation between GD/cancer phenotype and the systemic burden of glucocerebroside-laden macrophages. Therefore, we hypothesized that genetic modifier(s) may underlie the GD/cancer phenotype. In the present study, the genetic basis of GD/T-cell acute lymphoblastic lymphoma in 2 affected siblings was deciphered through genomic analysis. GBA gene sequencing revealed homozygosity for a novel mutation, D137N. Whole-exome capture and massively parallel sequencing combined with homozygosity mapping identified a homozygous novel mutation in the MSH6 gene that leads to constitutional mismatch repair deficiency syndrome and increased cancer risk. Enzyme studies demonstrated that the D137N mutation in GBA is a pathogenic mutation, and immunohistochemistry confirmed the absence of the MSH6 protein. Therefore, precise phenotype annotation followed by individual genome analysis has the potential to identify genetic modifiers of GD, facilitate personalized management, and provide novel insights into disease pathophysiology.

UI MeSH Term Description Entries
D007206 Individuality Those psychological characteristics which differentiate individuals from one another. Individual Differences,Difference, Individual,Differences, Individual,Individual Difference
D008297 Male Males
D010375 Pedigree The record of descent or ancestry, particularly of a particular condition or trait, indicating individual family members, their relationships, and their status with respect to the trait or condition. Family Tree,Genealogical Tree,Genealogic Tree,Genetic Identity,Identity, Genetic,Family Trees,Genealogic Trees,Genealogical Trees,Genetic Identities,Identities, Genetic,Tree, Family,Tree, Genealogic,Tree, Genealogical,Trees, Family,Trees, Genealogic,Trees, Genealogical
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D005776 Gaucher Disease An autosomal recessive disorder caused by a deficiency of acid beta-glucosidase (GLUCOSYLCERAMIDASE) leading to intralysosomal accumulation of glycosylceramide mainly in cells of the MONONUCLEAR PHAGOCYTE SYSTEM. The characteristic Gaucher cells, glycosphingolipid-filled HISTIOCYTES, displace normal cells in BONE MARROW and visceral organs causing skeletal deterioration, hepatosplenomegaly, and organ dysfunction. There are several subtypes based on the presence and severity of neurological involvement. Cerebroside Lipidosis Syndrome,Gaucher Disease Type 1,Gaucher Disease Type 2,Glucocerebrosidase Deficiency Disease,Glucosylceramide Beta-Glucosidase Deficiency Disease,Neuronopathic Gaucher Disease,Acid beta-Glucosidase Deficiency,Acid beta-Glucosidase Deficiency Disease,Acute Neuronopathic Gaucher Disease,Chronic Gaucher Disease,GBA Deficiency,Gaucher Disease Type 3,Gaucher Disease, Acute Neuronopathic,Gaucher Disease, Acute Neuronopathic Type,Gaucher Disease, Chronic,Gaucher Disease, Chronic Neuronopathic Type,Gaucher Disease, Infantile,Gaucher Disease, Infantile Cerebral,Gaucher Disease, Juvenile,Gaucher Disease, Juvenile and Adult, Cerebral,Gaucher Disease, Neuronopathic,Gaucher Disease, Non-Neuronopathic Form,Gaucher Disease, Noncerebral Juvenile,Gaucher Disease, Subacute Neuronopathic Form,Gaucher Disease, Subacute Neuronopathic Type,Gaucher Disease, Type 1,Gaucher Disease, Type 2,Gaucher Disease, Type 3,Gaucher Disease, Type I,Gaucher Disease, Type II,Gaucher Disease, Type III,Gaucher Splenomegaly,Gaucher Syndrome,Gaucher's Disease,Gauchers Disease,Glucocerebrosidase Deficiency,Glucocerebrosidosis,Glucosyl Cerebroside Lipidosis,Glucosylceramidase Deficiency,Glucosylceramide Beta-Glucosidase Deficiency,Glucosylceramide Lipidosis,Infantile Gaucher Disease,Kerasin Histiocytosis,Kerasin Lipoidosis,Kerasin thesaurismosis,Lipoid Histiocytosis (Kerasin Type),Non-Neuronopathic Gaucher Disease,Subacute Neuronopathic Gaucher Disease,Type 1 Gaucher Disease,Type 2 Gaucher Disease,Type 3 Gaucher Disease,Cerebroside Lipidoses, Glucosyl,Cerebroside Lipidosis Syndromes,Cerebroside Lipidosis, Glucosyl,Deficiencies, GBA,Deficiencies, Glucocerebrosidase,Deficiency Disease, Glucocerebrosidase,Deficiency Diseases, Glucocerebrosidase,Deficiency, GBA,Deficiency, Glucocerebrosidase,Disease, Chronic Gaucher,Disease, Gaucher,Disease, Gaucher's,Disease, Gauchers,Disease, Glucocerebrosidase Deficiency,Disease, Infantile Gaucher,Disease, Juvenile Gaucher,Disease, Neuronopathic Gaucher,Disease, Non-Neuronopathic Gaucher,Diseases, Gauchers,Diseases, Glucocerebrosidase Deficiency,GBA Deficiencies,Gaucher Disease, Non Neuronopathic Form,Gaucher Disease, Non-Neuronopathic,Gauchers Diseases,Glucocerebrosidase Deficiencies,Glucocerebrosidase Deficiency Diseases,Glucocerebrosidoses,Glucosyl Cerebroside Lipidoses,Glucosylceramide Lipidoses,Histiocytoses, Kerasin,Histiocytoses, Lipoid (Kerasin Type),Histiocytosis, Kerasin,Histiocytosis, Lipoid (Kerasin Type),Juvenile Gaucher Disease,Kerasin Histiocytoses,Kerasin Lipoidoses,Kerasin thesaurismoses,Lipidoses, Glucosyl Cerebroside,Lipidoses, Glucosylceramide,Lipidosis Syndrome, Cerebroside,Lipidosis Syndromes, Cerebroside,Lipidosis, Glucosyl Cerebroside,Lipidosis, Glucosylceramide,Lipoid Histiocytoses (Kerasin Type),Lipoidoses, Kerasin,Lipoidosis, Kerasin,Non Neuronopathic Gaucher Disease,Splenomegaly, Gaucher,Syndrome, Cerebroside Lipidosis,Syndrome, Gaucher,Syndromes, Cerebroside Lipidosis,thesaurismoses, Kerasin,thesaurismosis, Kerasin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Sarah M Lo, and Murim Choi, and Jun Liu, and Dhanpat Jain, and Rolf G Boot, and Wouter W Kallemeijn, and Johannes M F G Aerts, and Farzana Pashankar, and Gary M Kupfer, and Shrikant Mane, and Richard P Lifton, and Pramod K Mistry
June 2010, Journal of inherited metabolic disease,
Sarah M Lo, and Murim Choi, and Jun Liu, and Dhanpat Jain, and Rolf G Boot, and Wouter W Kallemeijn, and Johannes M F G Aerts, and Farzana Pashankar, and Gary M Kupfer, and Shrikant Mane, and Richard P Lifton, and Pramod K Mistry
September 1995, The Journal of pediatrics,
Sarah M Lo, and Murim Choi, and Jun Liu, and Dhanpat Jain, and Rolf G Boot, and Wouter W Kallemeijn, and Johannes M F G Aerts, and Farzana Pashankar, and Gary M Kupfer, and Shrikant Mane, and Richard P Lifton, and Pramod K Mistry
January 2011, Blood cells, molecules & diseases,
Sarah M Lo, and Murim Choi, and Jun Liu, and Dhanpat Jain, and Rolf G Boot, and Wouter W Kallemeijn, and Johannes M F G Aerts, and Farzana Pashankar, and Gary M Kupfer, and Shrikant Mane, and Richard P Lifton, and Pramod K Mistry
October 1999, Molecular genetics and metabolism,
Sarah M Lo, and Murim Choi, and Jun Liu, and Dhanpat Jain, and Rolf G Boot, and Wouter W Kallemeijn, and Johannes M F G Aerts, and Farzana Pashankar, and Gary M Kupfer, and Shrikant Mane, and Richard P Lifton, and Pramod K Mistry
September 2014, Science translational medicine,
Sarah M Lo, and Murim Choi, and Jun Liu, and Dhanpat Jain, and Rolf G Boot, and Wouter W Kallemeijn, and Johannes M F G Aerts, and Farzana Pashankar, and Gary M Kupfer, and Shrikant Mane, and Richard P Lifton, and Pramod K Mistry
January 1982, Progress in clinical and biological research,
Sarah M Lo, and Murim Choi, and Jun Liu, and Dhanpat Jain, and Rolf G Boot, and Wouter W Kallemeijn, and Johannes M F G Aerts, and Farzana Pashankar, and Gary M Kupfer, and Shrikant Mane, and Richard P Lifton, and Pramod K Mistry
March 2000, Archives of disease in childhood. Fetal and neonatal edition,
Sarah M Lo, and Murim Choi, and Jun Liu, and Dhanpat Jain, and Rolf G Boot, and Wouter W Kallemeijn, and Johannes M F G Aerts, and Farzana Pashankar, and Gary M Kupfer, and Shrikant Mane, and Richard P Lifton, and Pramod K Mistry
June 2017, Neurology. Genetics,
Sarah M Lo, and Murim Choi, and Jun Liu, and Dhanpat Jain, and Rolf G Boot, and Wouter W Kallemeijn, and Johannes M F G Aerts, and Farzana Pashankar, and Gary M Kupfer, and Shrikant Mane, and Richard P Lifton, and Pramod K Mistry
May 1986, Journal of virology,
Sarah M Lo, and Murim Choi, and Jun Liu, and Dhanpat Jain, and Rolf G Boot, and Wouter W Kallemeijn, and Johannes M F G Aerts, and Farzana Pashankar, and Gary M Kupfer, and Shrikant Mane, and Richard P Lifton, and Pramod K Mistry
April 2010, Journal of inherited metabolic disease,
Copied contents to your clipboard!